ストックスクリーナーアプリを入手
141.43
0.43%
-0.2622
Celcuity Inc (CELC) 最新ニュース
Is It Too Late To Consider Celcuity (CELC) After A 13x One Year Surge? - Yahoo Finance
ASCO 2026 preview – Celcuity gets a mutant coup | ApexOncoClinical Trials news and analysis - Oncology Pipeline
Celcuity reports Phase III VIKTORIA-1 trial results for breast cancer - Clinical Trials Arena
Celcuity’s gedatolisib beats Novartis drug in Phase III test - The Pharma Letter
CELC Stock Jumps As VIKTORIA-1 Trial Hits Key Goal - timothysykes.com
CELC Stock Jumps As VIKTORIA-1 Data Fuel FDA Push - StocksToTrade
Celcuity Stock Jumps 16% as Gedatolisib Breast-Cancer Data Raise FDA Stakes - TechStock²
CELC Stock Jumps As VIKTORIA-1 Phase 3 Data Impress Wall Street - timothysykes.com
Why is Celcuity stock rallying today? - MSN
Celcuity strengthens case for ASCO-spotlighted breast cancer drug - BioPharma Dive
Celcuity CELC Soars On Strong Phase 3 Cancer Data - StocksToTrade
Stifel raises Celcuity stock price target on trial data strength - Investing.com UK
Celcuity rises on gedatolisib on top-line data in breast cancer - BioWorld News
Celcuity shares jump 15.5% as Phase 3 VIKTORIA-1 topline results support potential label expansion path for gedatolisib - Quiver Quantitative
Wall Street believes Celcuity could become an acquisition target – why this analyst raised their price target by a whopping 76% - MSN
CELC Stock Surges As VIKTORIA-1 Trial Hits Phase 3 Milestone - timothysykes.com
Celcuity upgraded by H.C. Wainwright with a new price target - Quantisnow
Citizens raises Celcuity stock price target on Phase 3 trial win By Investing.com - Investing.com South Africa
Citizens raises Celcuity stock price target on Phase 3 trial win - Investing.com
Celcuity’s breast cancer win; Odyssey plans $205M IPO - Endpoints News
Needham raises Celcuity stock price target to $157 on trial data By Investing.com - Investing.com India
Needham raises Celcuity stock price target to $157 on trial data - Investing.com UK
Celcuity Stock Soars 14% to $143 on Positive Phase 3 Breast Cancer Trial Data - International Business Times Australia
Guggenheim raises Celcuity stock price target on trial success By Investing.com - Investing.com Canada
Guggenheim raises Celcuity stock price target on trial success - Investing.com
Stifel raises Celcuity stock price target on trial data strength By Investing.com - Investing.com Australia
Celcuity upgraded to Buy from Neutral at H.C. Wainwright - TipRanks
Celcuity Shares Climb on Positive Breast-Cancer Drug Trial Results - marketscreener.com
Celcuity price target raised to $157 from $122 at Needham - TipRanks
This Airbnb Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday - Benzinga
Wall Street Believes Celcuity Could Become An Acquisition Target – Why This Analyst Raised Their Price Target By A Whopping 76% - Stocktwits
Why Is Celcuity Stock Rallying Today? - Benzinga
As FDA decision nears, Celcuity posts win in PIK3CA-mutant breast cancer - FirstWord Pharma
Why Celcuity’s Hot Cancer Drug Stock Is Sinking - TipRanks
CELC stock jumps after hours on positive breast cancer trial data - MSN
Celcuity Stock Surges on Breakthrough Trial Results - TipRanks
Celcuity’s Gedatolisib Achieves Phase 3 Success in PIK3CA-Mutant HR+/HER2- Advanced Breast Cancer, Meeting Primary Endpoint in VIKTORIA-1 Trial 1 - Minichart
LifeSci Capital Maintains Celcuity(CELC.US) With Buy Rating, Maintains Target Price $165 - Moomoo
CELC Stock Jumps After Hours On Positive Breast Cancer Trial Data - Stocktwits
Jennison Associates LLC Purchases Shares of 229,704 Celcuity, Inc. $CELC - MarketBeat
LifeSci Capital Maintains Celcuity(CELC.US) With Buy Rating, Raises Target Price to $165 - Moomoo
Celcuity Reports Positive Phase 3 Results for Gedatolisib - TipRanks
Why Celcuity Shares Are Dropping After Big Trial Win - TipRanks
Celcuity reports positive phase 3 trial results for gedatolisib By Investing.com - Investing.com Nigeria
Celcuity announced that its Phase III Viktoria-1 clinical trial has successfully achieved the primary endpoint in the Pik3CA mutant patient cohort. - Bitget
Celcuity's Phase 3 VIKTORIA-1 Trial Achieves Primary Endpoint With Clinically Meaningful Improvement in Progression-Free Survival in PIK3CA Mutant Cohort - The Manila Times
Celcuity reports positive phase 3 trial results for gedatolisib - Investing.com
Celcuity's Phase 3 VIKTORIA-1 Trial Achieves Primary Endpoint With Clinically Meaningful ... - Caledonian Record
Celcuity's Phase 3 VIKTORIA-1 Trial Achieves Primary - GlobeNewswire
Biotech Stocks To Follow TodayMay 1st - MarketBeat
Celcuity (CELC) Is Up 6.9% After FDA Grants Priority Review For Gedatolisib And Debt FinancingHas The Bull Case Changed? - simplywall.st
CELC.O Technical Analysis & Stock Price Forecast - Intellectia AI
(CELC) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Celcuity: Best-In-Class Potential With 2–3x Upside If Mutant Data Delivers (NASDAQ:CELC) - Seeking Alpha
Celcuity Stock Gets First Analyst Coverage: $150 Price Target, FDA Decision Near for GedatolisibNews and Statistics - IndexBox
Why Celcuity Stock Popped on Monday - AOL.com
Celcuity LLC stock reaches all-time high at 128.29 USD By Investing.com - Investing.com South Africa
Why Celcuity stock popped on Monday - MSN
0.78%
3.01%
大文字化:
|
ボリューム (24 時間):